| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Molecular Medicine Program, 2 Mayo Clinic Cancer Center, and 3 Department of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota
Live attenuated Edmonston B strain of measles virus (MV-Edm) is a potent and specific oncolytic agent, but the mechanism underlying its tumor selectivity is unknown. The virus causes cytopathic effects (CPEs) of extensive syncytial formation in tumor cells but minimal damage or cell killing in normal cells. The CPE is dependent on expression of viral proteins and the presence of CD46, the major cellular receptor of MV-Edm. Using a virally encoded soluble marker peptide to provide a quantitative readout of the level of viral gene expression, we determined that tumor cells and normal cells expressed comparable levels of viral proteins. CD46 mediates virus attachment, entry, and virus-induced cell-to-cell fusion. Using engineered cells expressing a range of CD46 densities, we determined that whereas virus entry increased progressively with CD46 density, cell fusion was minimal at low receptor densities but increased dramatically above a threshold density of CD46 receptors. It is well established that tumor cells express abundant CD46 receptors on their surfaces compared with their normal counterparts. Thus, at low CD46 densities typical of normal cells, infection occurs, but intercellular fusion is negligible. At higher densities typical of tumor cells, infection leads to extensive cell fusion. Intercellular fusion also results in enhancement of viral gene expression through recruitment of neighboring uninfected cells into the syncytium, further amplifying the CPE. Discrimination between high and low CD46 receptor density provides a compelling basis for the oncolytic specificity of MV-Edm and establishes MV-Edm as a promising CD46-targeted cancer therapeutic agent.
This article has been cited by other articles:
|
|
 |
|
  S. K. Carlson, K. L. Classic, E. M. Hadac, D. Dingli, C. E. Bender, B. J. Kemp, and S. J. Russell Quantitative Molecular Imaging of Viral Therapy for Pancreatic Cancer Using an Engineered Measles Virus Expressing the Sodium-Iodide Symporter Reporter Gene Am. J. Roentgenol., January 1, 2009; 192(1): 279 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, Y. Liu, Z. Li, S. Tuve, D. Stone, O. Kalyushniy, D. Shayakhmetov, C. L. M. Verlinde, T. Stehle, J. McVey, et al. In Vitro and In Vivo Properties of Adenovirus Vectors with Increased Affinity to CD46 J. Virol., November 1, 2008; 82(21): 10567 - 10579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gauvrit, S. Brandler, C. Sapede-Peroz, N. Boisgerault, F. Tangy, and M. Gregoire Measles Virus Induces Oncolysis of Mesothelioma Cells and Allows Dendritic Cells to Cross-Prime Tumor-Specific CD8 Response Cancer Res., June 15, 2008; 68(12): 4882 - 4892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hasegawa, C. Hu, T. Nakamura, J. D. Marks, S. J. Russell, and K.-W. Peng Affinity Thresholds for Membrane Fusion Triggering by Viral Glycoproteins J. Virol., December 1, 2007; 81(23): 13149 - 13157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Liu, J. N. Sarkaria, C. A. Petell, G. Paraskevakou, P. J. Zollman, M. Schroeder, B. Carlson, P. A. Decker, W. Wu, C. D. James, et al. Combination of Measles Virus Virotherapy and Radiation Therapy Has Synergistic Activity in the Treatment of Glioblastoma Multiforme Clin. Cancer Res., December 1, 2007; 13(23): 7155 - 7165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Allen, S. Vongpunsawad, T. Nakamura, C. D. James, M. Schroeder, R. Cattaneo, C. Giannini, J. Krempski, K.-W. Peng, J. M. Goble, et al. Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor Specificity Cancer Res., December 15, 2006; 66(24): 11840 - 11850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tuve, H. Wang, C. Ware, Y. Liu, A. Gaggar, K. Bernt, D. Shayakhmetov, Z. Li, R. Strauss, D. Stone, et al. A New Group B Adenovirus Receptor Is Expressed at High Levels on Human Stem and Tumor Cells J. Virol., December 15, 2006; 80(24): 12109 - 12120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hasegawa, T. Nakamura, M. Harvey, Y. Ikeda, A. Oberg, M. Figini, S. Canevari, L. C. Hartmann, and K.-W. Peng The Use of a Tropism-Modified Measles Virus in Folate Receptor-Targeted Virotherapy of Ovarian Cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6170 - 6178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. D. Iankov, M. Pandey, M. Harvey, G. E. Griesmann, M. J. Federspiel, and S. J. Russell Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J. Virol., September 1, 2006; 80(17): 8530 - 8540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Seki, M. Takeda, H. Minagawa, and Y. Yanagi Recombinant wild-type measles virus containing a single N481Y substitution in its haemagglutinin cannot use receptor CD46 as efficiently as that having the haemagglutinin of the Edmonston laboratory strain J. Gen. Virol., June 1, 2006; 87(6): 1643 - 1648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Reddy, S. Ganesh, and D.-C. Yu Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. Clin. Cancer Res., May 1, 2006; 12(9): 2869 - 2878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hasegawa, L. Pham, M. K. O'Connor, M. J. Federspiel, S. J. Russell, and K.-W. Peng Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin. Cancer Res., March 15, 2006; 12(6): 1868 - 1875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Frankel, G. P. Cosgrove, S.-I. Cha, C. D. Cool, M. W. Wynes, B. L. Edelman, K. K. Brown, and D. W. H. Riches TNF-{alpha} Sensitizes Normal and Fibrotic Human Lung Fibroblasts to Fas-Induced Apoptosis Am. J. Respir. Cell Mol. Biol., March 1, 2006; 34(3): 293 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chernajovsky, L. Layward, and N. Lemoine Fighting cancer with oncolytic viruses BMJ, January 21, 2006; 332(7534): 170 - 172. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Heinzerling, V. Kunzi, P. A. Oberholzer, T. Kundig, H. Naim, and R. Dummer Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells Blood, October 1, 2005; 106(7): 2287 - 2294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Russell Measles Virus: A Potent, Versatile, Retargetable Oncolytic Platform Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 389 - 394. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
